Sanofi is a toxic dying company. Look at how it ruined Genzyme after taking over. Is hemorrhaging massive portfolios/$ in diabetes and others. Failed in its last 7 straight drug launches. 40% of its top executive leadership has quit the last 3 months. It is bloated 110,000 employees, 30,000 more employees than Pfizer despite far less revenue. The new CEO Brandicourt is desperate to leech/buy something good outside. One thing Sanofi is good at, to be fair, are cut-throat legal teams.
Better hope Sanofi doesn't acquire
- Thread starter anonymous
- Start date
-
- Tags
- None
Sanofi withdrew their consent for solicitation and got shown what foolish chumps they are after the shareholders said loud and clear SHOW US THE MONEY. Medivation will be bought but it won't be by Sanofi. They are up against bigger fish now.
Biggest fish ? Well Sanofi is the 4th largest company in the world so unless you mean Pfizer or j&j than there are no bigger sorry get a clue
"...unless you mean Pfizer or j&j than there are no bigger sorry get a clue"
Actually, Pfizer signed a confidentiality agreement. If we're not talking "bigger" fish, then let's talk about "generous" fish. Sanofi's been quite the cheapskate; yet another lowball offer will ruin their chances and since the Sanofi CEO needs to revive his sagging company, his BOD won't be pleased if he blows it.
Actually, Pfizer signed a confidentiality agreement. If we're not talking "bigger" fish, then let's talk about "generous" fish. Sanofi's been quite the cheapskate; yet another lowball offer will ruin their chances and since the Sanofi CEO needs to revive his sagging company, his BOD won't be pleased if he blows it.
This, Sanofi is notoriously cheap. They have to go big or go home if they want to compete.
Fucking dumbshit.
Just because you are scared that You will be working for Sanofi soon doesn't mean that you can just throw out random statements that are baseless. Sanofi is the 4th largest company in the world and can buy and sell mdvn 10 times over.
If we want your little prostate med we will take it .
Who's scared? Sanofi's failed miserably in their attempts so far...by bidding against themselves and having BOTH offers rejected. INGENIOUS!!!!!!
Gosh...nice comeback. Is that the corporate equivalent to "I'm rubber, you're glue...."?
Take it as a given that sanofi eventually will succeed. They have excellent records in this m&a business and know very well what they are doing.
Already a done deal with Sanofi, stay tuned for announcement before Labor Day!
We are getting close to the Mid Aug deadline for the company imposed merger deadline. News today that lawfirm is seaking class action suit. Sanofi thinks they can get out of partner deal with Astellas. I can't wait to see Astellas leadership (former Aventis) blow Sanofi out of the water.
How deep inside your ass did you need to reach to pull out that little nugget of insider info?
all of the detail about Xtandi notwithstanding, Hung's silence on the topic of a potential acquisition by Sanofi was glaringly obvious, but not unexpected. Last month, Medivation entered takeover talks with Sanofi after rejecting a previous $9.3 billion bid. Analyst's expect the deal to close in 2016 with Medivation's assets being transferred to Sanofi facilities early in 2017.
"This wasn't a terribly meaningful earnings call in terms of newsflow, since management (understandably) did not comment on the topic everyone wanted to hear about: the ongoing M&A discussions with Sanofi and other biopharma players that have signed CDAs with Medivation," wrote RBC Capital Markets analysts Simos Simeonidis in a recent note.
"We expect Medivation to be acquired this year, the cash flow and pipeline assets are of value to any larger company. Typically the Hart Scott Rodino review can close quickly when a small biotech company is being absorbed." said Irving Fentwick biotech analyst at Dilweed Advisors.
"Aside from that topic, and despite not commenting on its interactions with FDA, management appeared optimistic on the outcome of the 10/22/16 PDUFA for Xtandi's label expansion. Quite frankly we're surprised the acquisition has taken so long."
"This wasn't a terribly meaningful earnings call in terms of newsflow, since management (understandably) did not comment on the topic everyone wanted to hear about: the ongoing M&A discussions with Sanofi and other biopharma players that have signed CDAs with Medivation," wrote RBC Capital Markets analysts Simos Simeonidis in a recent note.
"We expect Medivation to be acquired this year, the cash flow and pipeline assets are of value to any larger company. Typically the Hart Scott Rodino review can close quickly when a small biotech company is being absorbed." said Irving Fentwick biotech analyst at Dilweed Advisors.
"Aside from that topic, and despite not commenting on its interactions with FDA, management appeared optimistic on the outcome of the 10/22/16 PDUFA for Xtandi's label expansion. Quite frankly we're surprised the acquisition has taken so long."
Cool info, but it doesn't addresses a supposed class action lawsuit (by whom?) to allow the buyer of Medivation to take full ownership of a co-promoted asset XTANDI from Astellas. If that was actually the case then the value of Medivation would at least double for the other half of US revenues and ex-US revenues.
Meanwhile.....
http://www.reuters.com/article/us-medivation-m-a-exclusive-idUSKCN10S1SW
Hear that soft "whooshing" sound? I think....I THINK....that's the sound of Brandicourt's balls retreating back inside him.
http://www.reuters.com/article/us-medivation-m-a-exclusive-idUSKCN10S1SW
Hear that soft "whooshing" sound? I think....I THINK....that's the sound of Brandicourt's balls retreating back inside him.
MEDIVATION (MDVN) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty
http://www.businesswire.com/news/ho...ION-MDVN-SHAREHOLDER-ALERT-–-Andrews-Springer
http://www.businesswire.com/news/ho...ION-MDVN-SHAREHOLDER-ALERT-–-Andrews-Springer